Tumor cells with neuroendocrine features

"Tumor cells with neuroendocrine features" refer to a diverse category of neoplastic cells that show evidence of neuroendocrine differentiation by morphology, hormone production, or immunophenotype, found in neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs) across multiple organ systems (lung, gastrointestinal tract, pancreas, etc.). These cells are characterized by variable differentiation (well-differentiated in NETs and poorly differentiated in NECs), proliferation rate, and expression of neuroendocrine markers such as chromogranin, synaptophysin, and INSM1. Molecular profiling has revealed distinct subtypes based on key transcription factors (e.g., ASCL1, NEUROD1, POU2F3, YAP1, HNF4A), underlying considerable biological and clinical heterogeneity, and reflecting differences in response to therapies and prognosis. Because "tumor cells with neuroendocrine features" is not a single target but rather a classification, it covers a broad pathological spectrum with diverse drug sensitivities and challenges in therapeutic management. This entry represents a cell classification, not a molecular drug target; thus, it should not be defined as a canonical target molecule or receptor.

Other names

neuroendocrine tumor cellneuroendocrine carcinoma cellNET cellNEC cellcells with neuroendocrine differentiation

Cytotoxicity via DNA damage (platinum agents); Hormone secretion inhibition (somatostatin analogs); Immune modulation (immune checkpoint inhibitors); Targeted therapy for molecular alterations (e.g., BRAF mutations)